We are live on ! Find out more
AC

Aperimus Capital Portfolio holdings

AUM $62.2M
1-Year Est. Return 47.35%
This Fund
S&P 500
This Quarter Est. Return
+22.21%
1 Year Est. Return
+47.35%
3 Year Est. Return
+43.98%
5 Year Est. Return
+93.69%
10 Year Est. Return
AUM
$209M
AUM Growth
+$54.6M
Cap. Flow
+$20M
Cap. Flow %
9.6%
Top 10 Hldgs %
100%
Holding
5
New
Increased
2
Reduced
1
Closed
2

Sector Composition

Rank Sector Weight
1 Healthcare 0%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDY icon
1
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27.3B
$86.3M 41.39%
265,958
+73,100
+38% +$22.2M
SPY icon
2
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$84M 40.27%
272,281
+78,750
+41% +$23.1M
IWM icon
3
iShares Russell 2000 ETF
IWM
$82.2B
$38.3M 18.35%
267,172
-149,300
-36% -$19.6M
CTAS icon
4
Cintas
CTAS
$82.5B
-88,000
Closed -$3.81M
VAPO
5
DELISTED
Vapotherm, Inc. Common Stock
VAPO
-11,973
Closed -$1.8M

Similar funds

Aperimus Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Aperimus Capital held 5 positions worth $209M, up 36% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aperimus Capital deployed $20M of net new capital in Q2 2020, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 0% of assets, down from 1.2% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $19.6M trimmed.

  • Aperimus Capital added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $23.1M increase.
  • Aperimus Capital's biggest Q2 2020 reduction was iShares Russell 2000 ETF, cutting an estimated $19.6M.
  • Aperimus Capital fully exited Cintas in Q2 2020, selling an estimated $3.81M.
  • Aperimus Capital's ten largest holdings make up 100% of its $209M portfolio in Q2 2020.
  • Aperimus Capital opened 0 new positions and closed 2 in Q2 2020.
  • Aperimus Capital's portfolio value rose 36% quarter-over-quarter to $209M.

Based on Aperimus Capital's 13F filing for Q2 2020, filed 22 Jul 2020.